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Abstract
Purpose of Review Non-alcoholic fatty liver disease
(NAFLD) is the most common liver disease in the Western
world. Invasive liver biopsy remains the gold standardmethod
for the diagnosis and staging of NAFLD. The aim of this
review is to summarize recent research regarding imaging-
based assessment of NAFLD.
Recent Findings Novel methods such as controlled attenu-
ation parameter (CAP) and magnetic resonance imaging
proton-derived fat fraction (MRI-PDFF) appear promising
for steatosis assessment and are currently undergoing val-
idation in NAFLD. Fibrosis can be non-invasively
assessed by transient elastography (TE), which is currently
the best validated test in NAFLD. MR elastography (MRE)
appears very sensitive for fibrosis detection. No imaging
technique can accurately detect NASH.
Summary TE is inexpensive and relatively widely available
and can reliably exclude advanced fibrosis in NAFLD.
MRI offers the most promise for steatosis and fibrosis
quantification, but further validation of these techniques
is needed.
Keywords NAFLD . Steatosis . Fibrosis . Magnetic
resonance imaging . Transient elastography . Imaging .
Non-invasive test . Ultrasound
Introduction
Non-alcoholic fatty liver disease (NAFLD) is the leading
cause of liver disease worldwide and is estimated to affect
25% of the global population [1]. NAFLD is strongly as-
sociated with obesity, and its prevalence has dramatically
increased in the last few decades in parallel with rates of
obesity. The histological definition of NAFLD is the pres-
ence of triacylglycerol (TAG) droplets in > 5% of hepato-
cytes, in the absence of excessive alcohol consumption or
the use of steatogenic drugs [2]. Histologically, NAFLD
ranges in severity from steatosis alone (frequently know
as non-alcoholic fatty liver; NAFL) to steatohepatitis
(known as non-alcoholic steatohepatitis; NASH), where
steatosis is associated with hepatocellular injury, inflam-
mation and fibrosis. Approximately 40% of patients with
NAFLD will develop progressive fibrosis, which can result
in cirrhosis [3, 4]. The incidence of NAFLD-related cirrho-
sis complications, such as hepatocellular carcinoma and
portal hypertension, is increasing, and as a result,
NAFLD is projected to be the primary indication for liver
transplantation in the US by 2020 [5].
NAFLD has a variable prognosis with the majority of
patients having benign disease without associated liver-
related morbidity or mortality. It has been recently deter-
mined that the key factor predicting long-term prognosis in
patients with NAFLD is the stage of liver fibrosis [6, 7].
Recent studies have shown that individuals with advanced
fibrosis (F3–F4) due to NAFLD have a > 3-fold increased
risk of all-cause mortality, compared with a reference
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population [6, 7]. Therefore, assessment of liver fibrosis is
critical in all patients with NAFLD to determine prognosis
and appropriate management.
Liver biopsy remains the gold standard test to diagnose
and stage NAFLD, but it has many well-documented lim-
itations including the risk of complications, sampling error,
inter- and intra-observer variability in reading the histolo-
gy and the expense of the procedure [8]. Given the large
burden of NAFLD worldwide, there is a critical need for
simple and accurate non-invasive tests to diagnose hepatic
steatosis and stage liver fibrosis. This will help identify
individuals at the highest risk of progression so they can
be targeted for more aggressive lifestyle interventions or
treatments to slow disease progression. There is also an
urgent need for accurate quantitative non-invasive tests
for steatosis, hepatic inflammation and fibrosis to monitor
response to treatment. This is particularly important with
the recent development of several new drugs for NAFLD
that are going through advanced-phase clinical trials.
Currently, there is reliance on liver biopsy to monitor pa-
tients in the clinical trials, but this will not be practical
once these drugs are widely used.
There have been a number of recent advances in
imaging-based assessment of steatosis and fibrosis which
are likely to impact on clinical practice. This review aims
to highlight some of the recent, important advances in this
field and to discuss how these may change clinical
practice.
Grading and Staging of Liver Histology
as the Reference Standard
Table 1 shows the histological grading system for NAFLD
that is used as the reference standard in most of the recent
imaging studies. In the majority, imaging is compared with
liver biopsy using semi-quantitative scales for grading
steatosis (S0–3) and staging fibrosis (F0–4).
Radiographic Assessment of Steatosis
Ultrasound
Due to its wide availability and low cost, conventional
ultrasound is the most common first line tool for the as-
sessment of hepatic steatosis. A fatty liver appears
“bright” compared with surrounding structures due to he-
patic TAG deposition, resulting in increased acoustic in-
terfaces. A recent meta-analysis including 2815 patients
from 34 studies assessed the diagnostic accuracy of ultra-
sound compared with histology in patients with NAFLD.
Overall, ultrasound had reasonable sensitivity and speci-
ficity (84.8 and 93.6%, respectively) for detecting > 20–
30% steatosis [9]. The sensitivity of ultrasound for detect-
ing milder steatosis (5–10%) on liver biopsy was lower,
with values as low as 65% [9]. Ultrasound was also inac-
curate in differentiating fatty liver alone, from NASH and
liver fibrosis [9]. A clear limitation of ultrasound is its
operator dependency, and future studies should include
detailed reliability assessments, which are currently lack-
ing. Despite this, ultrasound remains a good first line im-
aging modality for the assessment of fatty liver. However,
as ultrasound is insensitive for mild steatosis, if an indi-
vidual is strongly suspected of having NAFLD clinically
and the ultrasound is reported as normal, then second line
imaging modalities should be considered to reduce missed
diagnoses.
Controlled Attenuation Parameter
Controlled attenuation parameter (CAP) is a novel ultra-
sound technique that measures steatosis simultaneously
with liver stiffness during vibration-controlled transient
elastography using the FibroScan™ (Echosens, Paris,
France) M or XL Probe. It is known that hepatic steatosis
alters the propagation of ultrasound waves through the
liver, and CAP measures these physical changes, giving
an estimate of steatosis. Results of CAP range from 100
to 400 dB/m [10]. The first study describing the efficacy
of CAP was published in 2010 and included 115 patients
with liver disease from multiple etiologies. In that study,
there was a close relationship between CAP and histolog-
ical assessment of steatosis (r2 = 0.81). Moreover, CAP
accurately detected > 10 and > 33% steatosis with
AUROCs of 0.91 and 0.95, respectively [10]. A subse-
quent larger study of 153 patients with chronic liver dis-
ease and body mass index ≥ 28 kg/m2 found that the
optimum cut-off for detecting > 10% steatosis was
283 dB/m giving a sensitivity and specificity of 76 and
79%, respectively [11]. However, CAP had limited ability
to differentiate between specific grades of steatosis, par-
ticularly between grades 2 and 3 [11].
Table 1 Histological grading of steatosis and staging fibrosis,
according to the NASH CRN [60]
Steatosis grade (S0–3) Fibrosis (F0–4)
S0: 0–5% F0: None
S1: 5–33% F1a: Zone 3 mild perisinusoidal
F1b: Zone 3 moderate perisinusoidal
F1c: Periportal/portal only
S2: 34–66% F2: Perisinusoidal and portal/periportal
S3: > 66% F3: Bridging fibrosis
F4: Cirrhosis
F3–4 = advanced fibrosis
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The largest prospective study assessing CAP in
NAFLD included 261 patients and explored the relation-
ship between CAP and steatosis grade (S0 to S3) and also
looked at discordance rates and factors associated with
discordance [12]. Overall, CAP values for S0, S1, S2
and S3 were 264 ± 45, 298 ± 48, 331 ± 37 and
336 ± 31 dB/m, respectively [12]. Significantly higher
CAP values were seen in patients with S2/S3 steatosis
compared to S1 (333 versus 285 dB/m; p < 0.001), and
the AUROC of CAP to detect ≥ S2 and S3 was 0.8 and
0.66, respectively [12]. The optimal CAP cut-off for ≥ S2
disease was 310 dB/m [12], which provided a correct
assessment of S2/S3 in 86% of the cohort [12].
Discordance of at least one grade between CAP and his-
tology was observed in 31% of the patients.
A meta-analysis including nine studies assessing CAP
in patients with chronic liver disease of varying etiologies
found overall summary sensitivity and specificity values
of 78 and 79% for ≥ S1, 85 and 79% for ≥ S2 and 83 and
79% for S3 [13]. A limitation of this study was that CAP
cut-off values were different across the studies and were
not validated [13]. In order to address the limitations of
this study, a meta-analysis of individual patient data was
conducted to establish CAP cut-off values for the diagno-
sis of steatosis and define values for distinguishing be-
tween steatosis grades [14•]. Data from 19/21 eligible
studies were available, including 2735 patients (> 500
with NAFLD) with chronic liver disease [14•]. In this
study, optimal cut-offs were 248 and 268 for > S0 and
> S1, respectively [14•]. This study also found that disease
etiology may influence the CAP reading, with higher CAP
values (by 10 dB/m) for the same grade of steatosis seen
in patients with NAFLD compared with individuals with
hepatitis B and C [14•].
A major limitation of CAP is its failure rate, which
occurred in approximately 20% of the patients with
NAFLD [13]. This was higher than that reported for other
etiologies of liver disease where the rate was 7.7% [15].
Failure of CAP was associated with older age, BMI, pres-
ence of metabolic syndrome and female gender, all of
which are frequently present in patients with NAFLD
[15]. The high failure rate in patients with NAFLD is
not surprising as until recently CAP was only available
on the FibroScan™ M probe. The development of CAP
on the XL probe may overcome these limitations [16, 17],
but further validation is needed.
Overall, CAP is a relatively simple and inexpensive
method for steatosis assessment that is reasonably accu-
rate for the diagnosis of steatosis. When combined with
other clinical assessments, it is likely to help clinicians
diagnose or exclude steatosis. It also has the advantage
that liver stiffness (discussed in the following texts) is
measured simultaneously, providing an assessment of
fibrosis at the same time. However, CAP appears to have
limited ability to differentiate between grades of steatosis
and therefore is unlikely to be accurate enough to monitor
changes in steatosis with treatment, although this has not
been formally assessed.
Magnetic Resonance Imaging–Proton-Derived Fat
Fraction (MRI PDFF)
There are a number of MR techniques that have been
described to measure steatosis, including MR spectrosco-
py (MRS) and conventional MR methods (Dixon in- and
out-of-phase imaging) [18]. Until recently, MRS has been
the most widely used modality to measure liver fat in
large population-based studies and some therapeutic trials
[19–24]. However, this technique requires specific exper-
tise and as a result has not been widely used in clinical
practice.
More recently, a new method of MRI has been devel-
oped called proton density fat fraction (PDFF) which im-
proves on Dixon in- and out-of-phase imaging [25].
Similar to other MR methods, this technique measures
steatosis by assessing the fraction of MRI-visible protons
bound to fat, divided by all protons bound to fat and water
in the liver. The advantage of magnetic resonance imag-
ing–proton-derived fat fraction (MRI-PDFF) over previ-
ous methods is that it gives a global assessment of liver
fat, whereas techniques, such as MR spectroscopy, mea-
sure fat from regions of interest within the liver, which
can be associated with sampling variability [26]. Recent
cross-sectional studies have shown that PDFF correlates
well with histological assessment of steatosis (r2 = 0.54,
p < 0.001 and r2 = 0.69, p < 0.001, respectively) [25, 27]
and can accurately distinguish between the presence or
absence of hepatic steatosis (AUROC of 0.989) [25].
MRI-PDFF also had good inter-examination accuracy for
whole liver assessment (ICC = 0.999; SD < 0.24%,
range < 0.45%) [28]. Furthermore, MRI-PDFF was shown
to have better inter- and intra-observer agreement com-
pared with histological steatosis grading (p < 0.001) [29].
MRI-PDFF has shown promise in longitudinal studies
assessing changes in steatosis with treatment [30–32]. In
the FLINT study, a randomized controlled trial (RCT) of
obeticholic acid vs. placebo for 72 weeks, MRI-PDFF
accurately differentiated steatosis S0–1 from S2–3
(AUROC 0.95) and S0–2 from S3 (AUROC 0.96) at
baseline [33•]. At 90% specificity, MRI-PDFF cut-off
values were 16.3% (83% sensitivity) and 21.7% (84%
sensitivity) for distinguishing histological steatosis S0–1
from 2 to 3 and S0–2 from S3, respectively [33•]. At
week 72 of treatment, 49% of patients had no change in
histological steatosis grade (mean PDFF change
+ 0.3% ± 6.3%), 9% of patients had increased steatosis
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grade (mean PDFF change + 7.7% ± 6.0%) and 42% of
patients had a reduction in steatosis grade (mean PDFF
change − 7.4% ± 8.7%) [33•]. PDFF change had
AUROCs of 0.81 for both a reduction and increase in
steatosis grade, respectively [33•]. There was also a good
relationship between change in PDFF and change in his-
tological steatosis grade (r2 = 0.63, p < 0.001) [33•].
A secondary analysis of the MOZART trial (RCT of
ezetimibe versus placebo for 24 weeks in NASH;
n = 50) showed a strong correlation between MRI-
PDFF and total l iver volume (TLV) (r = 0.57,
p < 0.0001) and MRI-PDFF and total liver fat index
(TLFI) (r = 0.94, p < 0.0001) at week 0 [31]. Patients
with grade 3 steatosis on index biopsy had significantly
higher PDFF, TLV and TFLI than those with grade 1
steatosis on index biopsy [31]. At week 24, the correla-
tions between the MRI measured indices remained sim-
ilar, indicating longitudinal reliability [31]. The change
in PDFF over the 24-week period also correlated signif-
icantly with change in TLV [31]. There was no signifi-
cant association between the change in TLV and change
in histological steatosis at 24 weeks [31]. The authors
speculated that within the context of other published
studies [32] [19], MRI-PDFF may be more responsive
than histological steatosis in detecting incremental hepat-
ic fat change. However, this was a small study, and the
authors used grade of steatosis, rather than percentage of
steatosis, to assess histology, which may have not been
sensitive enough to detect minor histological changes in
liver fat [34].
Two recent studies have directly compared MRI-PDFF
with CAP for quantifying hepatic steatosis [35••, 36••].
Both studies showed superiority of PDFF over CAP. In
the study by Park et al., MRI-PDFF more accurately de-
tected any steatosis than CAP (MRI-PDFF: AUROC 0.99
vs. CAP: AUROC 0.85) and was also more accurate than
CAP for identifying specific steatosis grades (p = 0.0091)
[36••]. Almost identical findings were seen in the other
well-conducted study from Japan [35••].
The relationship between MRI-PDFF and histological
hepatic steatosis becomes complicated when patients de-
velop advanced liver fibrosis. In the MOZART study,
mean PDFF trended downwards between F0–2 and F2–4
[31, 34]. It is known that MRI may underestimate the
amount of fat in hepatocytes when compared with histol-
ogy in those with more advanced fibrosis because the
number of hepatocytes per volume of liver is reduced,
leading to an apparent reduction in liver fat [37].
Therefore, it is likely that fibrosis stage will need to be
considered when measuring steatosis in patients with
chronic liver disease [37]. Concomitant assessment of liv-
er fibrosis and steatosis by MRI may overcome this need
[34], as discussed later in this review.
Overall, MRI-PDFF offers an accurate non-invasive as-
sessment of steatosis and may have a role in monitoring a
patient’s response to treatment. However, MR is expen-
sive, and there is already pressure on MRI scanners for
other indications; so, it may not be feasible to use these
techniques widely to diagnose and monitor steatosis.
However, MRI-PDFF is a useful tool to measure changes
in steatosis in clinical trials.
Radiographic Assessment of Liver Stiffness
as a Surrogate Biomarker of Fibrosis
Transient Elastography
Liver fibrosis can be staged using FibroScan™ (Echosens,
Paris, France), a one-dimensional ultrasound transient
elastography (TE), which measures the velocity of a
low-frequency (50 Hz) elastic shear wave, emitted from
the ultrasound probe, propagating through the liver [38].
The elastic modulus underpins the measure, i.e. the stiffer
the tissue, the faster the shear wave velocity. The liver
stiffness (LSM) is measured through a cylindrical volume
1 cm wide and 4 cm long, 2–7 cm below the skin surface.
Results are expressed as kilopascals (kPa) using the me-
dian of ten valid measurements with a range of 2.5–
75 kPa; normal liver has a value of < 5.5 kPa [38]. It is
the most commonly used and most validated imaging
method for non-invasive assessment of liver fibrosis cur-
rently available.
A recent meta-analysis of the use of TE in patients
with NAFLD (9 studies, 1047 patients) suggests that
TE has excellent diagnostic accuracy for cirrhosis (92%
specificity and 92% sensitivity), good accuracy for F3
(82% specificity and 85% sensitivity), but modest accu-
racy for F2 (75% specificity, 79% sensitivity) [39].
Despite this, TE can rule out cirrhosis with a high NPV
(~ 90%) [40]. One of the challenges of using TE is de-
termining the optimum cut-off for diagnosing a specific
stage of fibrosis. Generally, a very low LSM is very good
at ruling out significant liver fibrosis and a very high
LSM indicates cirrhosis with high probability. However,
intermediate LSM readings are less accurate, and the
choice of a specific cut-off becomes a real balance be-
tween specificity and sensitivity. For example, for a di-
agnosis of cirrhosis, LSM cut-offs between 10.3–
17.5 kPa will yield sensitivity of 78 to 100% and spec-
ificity of 82 to 98% [39]. Therefore, clinicians may use
different cut-offs for different stages of fibrosis in differ-
ent environments depending whether they want to ex-
clude or diagnose a fibrosis stage with high probability.
In general, a cut-off of < 8 kPa (or 7.2 kPa for the XL
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probe) reliably excludes advanced fibrosis (F3–4) and a
cut-off > 9.6 kPa is suggestive of F3–4.
A recent population-based, cross-sectional study illus-
trates the utility of TE as a non-invasive fibrosis marker in
detecting clinically relevant liver fibrosis in the communi-
ty. A total of 3041 participants (aged ≥ 45 years) from
Holland underwent TE with LSM ≥ 8.0 kPa, defined as
the surrogate marker of clinically relevant liver fibrosis
[41•]. Of those with reliable LSM, overall 169 (5.6%) dem-
onstrated LSM ≥ 8.0 kPa, and this increased to 8.4% in
participants with steatosis on ultrasonography and further
increased to 17.2% in those with steatosis and type 2 dia-
betes [41•]. These findings were consistent with another
prospective study from Hong Kong in diabetic patients
(n = 1918) which found that 17.7% of patients had an
increased LSM (≥ 9.6 kPa by M probe and ≥ 9.6 kPa by
XL probe) [42•]. Of those patients that underwent liver
biopsy, 50% were subsequently diagnosed with advanced
fibrosis [42•]. Both these studies indicated the potential to
use TE in the community to identify individuals with un-
diagnosed significant liver disease.
Although the value of TE is clear, it is now recognized
that hepatic steatosis has an impact on the accuracy of
LSM. This was demonstrated in a recent study of 253
patients with NAFLD, which showed that patients without
significant fibrosis (F0–F1) or severe fibrosis (F0–F2) had
a higher rate of false-positive LSM results for F3–4 when
severe steatosis (≥ 66%) was present compared to those
with lesser degrees of steatosis (F0–F1 23.6 vs. 14.9%,
F0–F2 33.3 vs. 13.2%, respectively) [43•]. Building on
these findings, another study assessed the effect of CAP
values on accuracy of LSM in 324 patients with NAFLD
using the M probe [44]. CAP values were classified into
tertiles (lower 132–298, middle 299–338, higher 339–
400 dB/m). Among patients with F0–F2, mean LSM
values increased according to CAP tertiles (6.8 versus
8.6 versus 9.4, p < 0.001). Moreover AUROCs for the
diagnosis of F3–F4 with LSM progressively reduced with
increasing CAP tertiles (0.915, 0.830 and 0.806), and
false-positive rates for F3–F4 increased with increasing
CAP (7.2% in lower versus 16.6% in middle versus
18.1% in higher CAP tertiles) [44]. Both studies elegantly
define the effect of steatosis on fibrosis prediction, but
further studies will need to assess the effect of CAP on
LSM values using the XL probe.
A major challenge of using TE in patients with NAFLD
is the failure rate (no/insufficient valid measurements) or
unreliable results (IQR/LSM ≥ 30% in patients with LSM
≥ 7.1 kPa), which was seen in 14.4 and 8.9% of cases,
respectively, in one of the recent well-conducted NAFLD
studies [45••]. In the largest series to date (≥ 13,000 exam-
inations in 7261 European patients), LSM failure and un-
reliable results were independently associated with BMI
≥ 30 kg/m2, age, hypertension, diabetes, operator experi-
ence and female gender [46].
As mentioned previously, the XL probe may overcome
some of the challenges posed by obese patients. This probe
emits a lower central ultrasound frequency, generating a
deeper region of interest. The failure rate of the XL probe
was significantly lower than that of the M probe (2 vs.
10%; p = 0.002), and reliable measurements were obtained
in 65% of obese individuals [47]. A study of patients from
France and Hong Kong showed it was possible to obtain
valid LSM readings in 91.2% participants using either the
M or XL probe [48•]. However, discordance of ≥ 2 fibrosis
stages between histology and LSM occurred in 11% of
patients using the XL probe, which was 4- to 5-fold more
frequent among patients with severe obesity (BMI ≥ 40 kg/
m2 32 vs. 8%) and liver stiffness > 7.0 kPa (20 vs. 4%)
[49]. It should be noted that LSM values generated by the
XL probe were lower per stage of fibrosis, and so, distinct
cut-off values are required [47, 49]. Finally, LSM may
predict long-term prognosis. In a study of 556 patients with
NAFLD followed for a median of 6.4 years, individuals
with higher LSM had significantly worse overall survival
and worse survival free from liver-related and extra-
hepatic complications [50•].
Acoustic Radiation Force Impulse (ARFI) Imaging
Acoustic radiation force impulse imaging (ARFI) is a form
of elastography that is performed on commercially avail-
able B-mode ultrasound machines [51]. ARFI generates
short duration acoustic impulses that excite tissues, and
the resulting shear wave velocity through the liver is mea-
sured giving a liver stiffness measurement. ARFI has the
advantage over TE of giving an assessment of the sono-
graphic appearance of the liver and other abdominal struc-
tures, as well as giving an estimate of liver fibrosis. A
systematic review of seven studies (723 NAFLD patients)
showed that ARFI was reasonably accurate for the detec-
tion of significant fibrosis (≥ F2) (AUROC 0.898; summa-
ry sensitivity and specificity 80.2 and 85.2%, respectively)
[52]. However, optimal cut-off values were not assessed in
this paper [52]. Much of the work in assessing ARFI as a
measure of liver fibrosis has been conducted in patients
with viral hepatitis, rather than NAFLD. Therefore, opti-
mum cut-offs for the diagnosis of varying stages of fibrosis
in NAFLD need to be validated. There are also different
versions of ARFI (such as Siemens Virtual Touch
Quantification™ and Phillips ElastPQ™), which may have
different diagnostic accuracies and different diagnostic cut-
offs. ElastPQ™ gives significantly lower ARFI readings
than the Virtual Touch quantification™ [53]; so, these fac-
tors need to be considered when using these techniques.
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Another variation of ultrasound elastography is
Supersonic Shear Imaging (SSI; Aixplorer, France),
which uses an ultrafast ultrasonic scanner [51]. This tech-
nique has shown real promise in the assessment of liver
fibrosis and performed better than TE in patients with
hepatitis C [54].
Comparison of Liver Stiffness Measurement Techniques
Only one study compared the diagnostic performance of
FibroScan™ M probe, ARFI (Siemens) and SSI in 291
patients with NAFLD using histology as the reference.
Overall, SSI performed best for the detection of signif-
icant fibrosis, advanced fibrosis and cirrhosis (AUROCs
for SSI, FibroScan™ and ARFI were 0.86, 0.82 and
0.77 for diagnoses of ≥ F2; 0.89, 0.86 and 0.84 for
≥ F3; and 0.88, 0.87 and 0.84 for F4; respectively)
[45••]. The results are similar to prior individual studies
[39, 55]. It appears that none of the three imaging
methods could accurately predict < F2 fibrosis, so fur-
ther optimization of ultrasound techniques is needed
[45••]. Failure rates were lower for ARFI (0.7%) than
for SSI or FibroScan™ (both p < 0.0001), whereas un-
reliable results were higher for ARFI (18.2%) than for
SSI or FibroScan™ (p = 0.0001 and p = 0.001, respec-
tively) [45••]. Further trials are needed to confirm the
utility of SSI in NAFLD.
Comparison of Liver Stiffness Measurement with Blood
Tests
TE was the best performing test (highest AUROC [0.83],
sensitivity [88%] and NPV [90%]) for F3–4 when compared
with eight blood fibrosis tests (BARD, NAFLD Fibrosis
Score, FibrometerNAFLD, aspartate aminotransferase to plate-
let ratio index (APRI), FIB4, FibroTest, Hepascore,
FibroMeterV2G) in a well-conducted study of 452 patients
with NAFLD [50•].
Magnetic Resonance Elastography (MRE)
Magnetic resonance elastography (MRE) is a novel meth-
od of elastographic assessment which uses a modified
phase-contrast pulse sequence to visualize the propagation
of a shear-wave deep into liver tissue, evaluating a large
portion of the liver [26]. A recent single-center prospec-
tive US study (117 patients) found that MRE very accu-
rately discriminated between F3–4 and F0–2 (AUROC
0.924, p < 0.0001), but it was less accurate for
distinguishing individual fibrosis stages [56••]. A thresh-
old of ≥ 3.63 kPa demonstrated a NPV and PPV of 97 and
68%, respectively, for a diagnosis of F3–4 [56••]. The
ability of MRE to discriminate between NASH from
non-NASH was modest (AUROC 0.73) [56••]. Recently,
a systematic review evaluated nine studies (232 NAFLD
patients) and found that the summary AUROCs for ≥ F1,
≥ F2, ≥ F3 and F4 were 0.86, 0.87, 0.90 and 0.91, respec-
tively [57].
Given its accuracy, MRE also may offer a good non-
invasive tool to monitor changes in liver fibrosis. In a
placebo-controlled trial of sitagliptin in NAFLD, MRE
was shown to have robust correlation coefficient between
baseline and 24 weeks [58]. Longitudinal studies of con-
temporaneous MRE and liver biopsy are underway, and
their results are eagerly awaited.
Comparison of Magnetic Resonance Elastography
with Ultrasound-Based Elastography
Two recent cross-sectional studies have compared the
effectiveness of MRE vs. TE for the diagnosis of liver
fibrosis in patients with NAFLD [35••, 36••]. The first
study, from Japan, assessed 142 patients and demonstrat-
ed that MRE was superior to TE for the diagnosis of
≥ F2 (AUROCs 0.91 vs. 0.82, respectively; p = 0.001)
and F4 (AUROCs 0.97 vs. 0.92; p = 0.049) [35••]. A
similar US-based study in 104 patients showed similar
findings in a more obese cohort [36••]. In that study,
the M or XL probe for TE was used where indicated,
whereas the Japanese study used the M probe only.
Overall, MRE had an AUROC of 0.82 for a diagnosis
of any fibrosis (F1–4), which was superior to TE
(AUROC 0.67). Using a threshold of 2.65 kPa, MRE
had a sensitivity of 76.5%, specificity of 79.1%, PPV
of 81.3% and NPV of 73.9% for a diagnosis of any
fibrosis [36••]. MRE was also more effective than TE
in diagnosing NASH (AUROC 0.70 vs. 0.35; p = 0.001)
[35••, 36••].
Overall, MRE and TE both perform well for a diagno-
sis of advanced fibrosis and cirrhosis, with MRE being
slightly superior. However, MRE outperforms TE for a
diagnosis of earlier stages of fibrosis. MRE does not ap-
pear to be affected by obesity and ascites, but inflamma-
tion and liver iron overload may cause inaccuracies in
MRE readings. The major limitation of MRE, when com-
pared with TE, is its cost, and as a result, it is not likely to
be widely used for the staging of NAFLD in the commu-
nity. However, when compared with liver biopsy, the cost
of MRE is much more acceptable, and as a result, special-
ist centers that have the technology available could
choose MRE as a second-line investigation for the staging
of NAFLD in those where they are considering a liver
biopsy. It is also likely that MRE combined with PDFF
will continue to be used in clinical trials to monitor re-
sponse to treatment.
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Multiparametric MRI
Another novel MRI technique that has been evaluated
is multiparametic MRI (liver MultiScan™, Perspectum
Diagnostics, Oxford, England), which assesses hepatic
steatosis, fibrosis and iron content. In a study of 79
unselected patients referred for liver biopsy, corrected
T1 images (cT1) were significantly different between
all fibrosis stages, except between mild and moderate
fibrosis [59]. In addition, steatosis measured by rapid
spectroscopy correlated strongly with semi-quantitative
steatosis scores (r2 = 0.89, p < 0.0001) [59]. Validation
of this technique in larger NAFLD cohorts is needed to
accurately assess the clinical utility of this technology.
Conclusions
With the large burden of disease (mostly undiagnosed) in
the community, NAFLD presents a major challenge to
healthcare providers. In order to try and reduce the burden
of advanced liver disease, it is important to identify indi-
viduals with significant fibrosis early so they can be ac-
tively managed to reduce fibrosis progression and, where
necessary, be screened for cirrhotic complications. In the
last 5 years, there has been significant progress in the
evaluation of imaging-based techniques to assess both
steatosis and fibrosis, with some of the technologies, such
as TE, entering routine clinical practice. A proposed algo-
rithm for the detection of steatosis and the assessment of
NAFLD severity using imaging is shown in Fig. 1, and a
summary of the different imaging modalities for steatosis
and fibrosis is shown in Table 2.
TE remains the most widely used imaging technique
for fibrosis, and low LSM values can reliably exclude
advanced fibrosis, while very high LSM readings indicate
cirrhosis with relative certainty. With the development of
CAP, steatosis can be assessed simultaneously with fibro-
sis, with reasonable accuracy. However, TE has modest
accuracy for the diagnosis of moderate liver fibrosis,
which is a particularly important stage to identify if pa-
tients are to receive “disease modifying” treatment.
Of the imaging techniques available, MRI offers the
most accurate method for the quantification of steatosis
(PDFF) and fibrosis (MRE). MRE is particularly accu-
rate, when compared with TE, in diagnosing milder
stages of fibrosis, which is helpful to identify individuals
before they have progressed to advanced fibrosis so they
can receive treatment. MR also has shown real promise in
clinical trials to monitor treatment response, but further
Individual with suspected NAFLD
(raised liver enzymes with central obesity,
individuals with the metabolic syndrome, T2DM etc)
Clinical assessment,
blood tests and
ultrasound Steatosis on ultrasound
Assess fibrosis with TE
Significant fibrosis
Suspected
LSM ≥8KPa
 Significant fibrosis
Excluded
 LSM < 8KPa
 
Lifestyle advice,
modify cardiovascular risk,
primary care follow up.
Reassess fibrosis in 3-5 years
Lifestyle advice,
modify cardiovascular risk,
active NAFLD management
(Vitamin E, Pioglitazone,
clinical trials etc)
 
Consider liver biopsy or
MRE to confirm if necessary
No steatosis on ultrasound
Second line steatosis assessment
CAP
MRI, PDFF or alternative if available
Steatosis
CAP ≥283 dB/m.
MRI visible steatosis
No Steatosis 
Reassure
(provided no evidence
of significant fibrosis and
reassess if the clinical
scenario changes)
Fig. 1 Proposed diagnostic algorithm for the detection of steatosis and assessment of NAFLD disease severity
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validation of these techniques is needed. However, criti-
cally, the cost-effectiveness, standardization and clinical
relevance of MRI evaluation need further study.
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